story of the week
Enzalutamide Is Clinically Active and Tolerable in AR-Expressing TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Enzalutamide For the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer
J. Clin. Oncol 2018 Jan 26;[EPub Ahead of Print], TA Traina, K Miller, DA Yardley, J Eakle, LS Schwartzberg, J O'Shaughnessy, W Gradishar, P Schmid, E Winer, C Kelly, R Nanda, A Gucalp, A Awada, L Garcia-Estevez, ME Trudeau, J Steinberg, H Uppal, IC Tudor, A Peterson, J CortesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.